Semen enhances transmitted/founder HIV-1 infection and only marginally reduces antiviral activity of broadly neutralizing antibodies

被引:0
|
作者
von Maltitz, Pascal [1 ]
Wettstein, Lukas [1 ]
Weil, Tatjana [1 ]
Schommers, Philipp [2 ,3 ,4 ,5 ,6 ,7 ]
Klein, Florian [2 ,3 ,4 ,5 ]
Muench, Jan [1 ]
机构
[1] Univ Ulm Med Ctr, Inst Mol Virol, Ulm, Germany
[2] Univ Cologne, Inst Virol, Fac Med, Lab Expt Immunol, Cologne, Germany
[3] Univ Hosp Cologne, Cologne, Germany
[4] German Ctr Infect Res, Cologne, Germany
[5] Ctr Mol Med Cologne CMMC, Cologne, Germany
[6] Univ Cologne, Fac Med, Dept Internal Med 1, Cologne, Germany
[7] Univ Cologne, Univ Hosp Cologne, Cologne, Germany
关键词
bNAb; HIV-1; semen; microbicide; DOUBLE-BLIND; VAGINAL GEL; PREVENTION; MICROBICIDES; PHASE-3;
D O I
10.1128/jvi.01190-23
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Topically applied microbicides may play a critical role in preventing sexual transmission of human immunodeficiency virus type 1 (HIV-1); however, their efficacy can be compromised by amyloid fibrils present in semen, which significantly increase HIV-1 infectivity. This phenomenon may have contributed to the failure of most microbicide candidates in clinical settings. Understanding the impact of semen on microbicide effectiveness is thus crucial. In our study, we evaluated the influence of semen on the neutralizing activity of broadly neutralizing antibodies (bNAbs), including PG16, PGT121, 10-1074, 3BNC117, and VRC01, which are potential microbicide candidates. We found that semen enhances infection of HIV-1 transmitted/founder viruses but only marginally affects the neutralizing activity of tested antibodies, suggesting their potential for microbicide application. Our findings underscore the need to consider semen-mediated enhancement when evaluating and developing microbicides and highlight the potential of incorporating HIV-1 bNAbs in formulations to enhance efficacy and mitigate HIV-1 transmission during sexual encounters.IMPORTANCEThis study examined the impact of semen on the development of microbicides, substances used to prevent the transmission of HIV-1 during sexual activity. Semen contains certain components that can render the virus more infectious, posing a challenge to microbicide effectiveness. Researchers specifically investigated the effect of semen on a group of powerful antibodies called broadly neutralizing antibodies, which can neutralize a large spectrum of different HIV-1 variants. The results revealed that semen only had a minimal effect on the antibodies' ability to neutralize the virus. This is promising because it suggests that these antibodies could still be effective in microbicides, even in the presence of semen. Understanding this interaction is crucial for developing better strategies to prevent HIV-1 transmission. By incorporating the knowledge gained from this study, scientists can now focus on creating microbicides that consider the impact of semen, bringing us closer to more effective prevention methods. This study examined the impact of semen on the development of microbicides, substances used to prevent the transmission of HIV-1 during sexual activity. Semen contains certain components that can render the virus more infectious, posing a challenge to microbicide effectiveness. Researchers specifically investigated the effect of semen on a group of powerful antibodies called broadly neutralizing antibodies, which can neutralize a large spectrum of different HIV-1 variants. The results revealed that semen only had a minimal effect on the antibodies' ability to neutralize the virus. This is promising because it suggests that these antibodies could still be effective in microbicides, even in the presence of semen. Understanding this interaction is crucial for developing better strategies to prevent HIV-1 transmission. By incorporating the knowledge gained from this study, scientists can now focus on creating microbicides that consider the impact of semen, bringing us closer to more effective prevention methods.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Neutralizing the threat: harnessing broadly neutralizing antibodies against HIV-1 for treatment and prevention
    Becerra, Juan C.
    Hitchcock, Lauren
    Vu, Khoa
    Gach, Johannes S.
    MICROBIAL CELL, 2024, 11 (01):
  • [42] Lessons from babies: inducing HIV-1 broadly neutralizing antibodies
    Georgia D Tomaras
    Barton F Haynes
    Nature Medicine, 2014, 20 : 583 - 585
  • [43] Requirements for the Induction of Broadly Neutralizing Antibodies against HIV-1 by Vaccination
    A. N. Vzorov
    L. V. Uryvaev
    Molecular Biology, 2017, 51 : 819 - 829
  • [44] Structural and Biochemical Characterization of Cysteinylation in Broadly Neutralizing Antibodies to HIV-1
    Omorodion, Oluwarotimi
    Wilson, Ian A.
    JOURNAL OF MOLECULAR BIOLOGY, 2021, 433 (24)
  • [45] Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies
    Haynes, BF
    Fleming, J
    St Clair, EW
    Katinger, H
    Stiegler, G
    Kunert, R
    Robinson, J
    Scearce, RM
    Plonk, K
    Staats, HF
    Ortel, TL
    Liao, HX
    Alam, SM
    SCIENCE, 2005, 308 (5730) : 1906 - 1908
  • [46] Towards HIV-1 remission: potential roles for broadly neutralizing antibodies
    Halper-Stromberg, Ariel
    Nussenzweigz, Michel C.
    JOURNAL OF CLINICAL INVESTIGATION, 2016, 126 (02): : 415 - 423
  • [47] HIV-1 cell-to-cell transmission and broadly neutralizing antibodies
    Dufloo, Jeremy
    Bruel, Timothee
    Schwartz, Olivier
    RETROVIROLOGY, 2018, 15
  • [48] FOCUS ON RESEARCH Broadly Neutralizing Antibodies for HIV-1 Prevention or Immunotherapy
    Caskey, Marina
    Klein, Florian
    Nussenzweig, Michel C.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (21): : 2019 - 2021
  • [49] Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers
    Elise Landais
    Penny L. Moore
    Retrovirology, 15
  • [50] Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning
    Peter D. Kwong
    John R. Mascola
    Gary J. Nabel
    Nature Reviews Immunology, 2013, 13 : 693 - 701